Skip to main content

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.

Publication ,  Journal Article
Balogh, EP; Bindman, AB; Eckhardt, SG; Halabi, S; Harvey, RD; Jaiyesimi, I; Miksad, R; Moses, HL; Nass, SJ; Schilsky, RL; Sun, S; Torrente, JM ...
Published in: Oncologist
March 2020

A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

March 2020

Volume

25

Issue

3

Start / End Page

e405 / e411

Location

England

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Pilot Projects
  • Pharmaceutical Preparations
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Drug Prescriptions
  • Drug Labeling
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Balogh, E. P., Bindman, A. B., Eckhardt, S. G., Halabi, S., Harvey, R. D., Jaiyesimi, I., … Warren, K. E. (2020). Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist, 25(3), e405–e411. https://doi.org/10.1634/theoncologist.2019-0698
Balogh, Erin P., Andrew B. Bindman, S Gail Eckhardt, Susan Halabi, R Donald Harvey, Ishmael Jaiyesimi, Rebecca Miksad, et al. “Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.Oncologist 25, no. 3 (March 2020): e405–11. https://doi.org/10.1634/theoncologist.2019-0698.
Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, et al. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 Mar;25(3):e405–11.
Balogh, Erin P., et al. “Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.Oncologist, vol. 25, no. 3, Mar. 2020, pp. e405–11. Pubmed, doi:10.1634/theoncologist.2019-0698.
Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 Mar;25(3):e405–e411.

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

March 2020

Volume

25

Issue

3

Start / End Page

e405 / e411

Location

England

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Pilot Projects
  • Pharmaceutical Preparations
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Drug Prescriptions
  • Drug Labeling
  • 3211 Oncology and carcinogenesis